Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism

Mitsuhide Naruse¹,², Akiyo Tanabe³, Koichi Yamamoto⁴, Hiromi Rakugi⁵, Mitsuhiro Kometani⁶, Takashi Yoneda⁵, Hiroki Kobayashi⁶, Masanori Abe⁶, Youichi Ohno⁷, Nobuya Inagaki⁷, Shoichiro Izawa⁸, Masakatsu Sone⁹

¹Endocrine Center and Clinical Research Center, Ijinkai Takeda General Hospital, Kyoto; ²Clinical Research Institute of Endocrinology and Metabolism, NHO Kyoto Medical Center; ³Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo; ⁴Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka; ⁵Department of Health Promotion and Medicine of the Future, Graduate School of Medical Sciences, Kanazawa University, Kanazawa; ⁶Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo; ⁷Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto; ⁸Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago; ⁹Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Adrenal venous sampling (AVS) is the key procedure for lateralization of primary hyperaldosteronism (PA) before surgery. Identification of the adrenal veins using computed tomography (CT) and intraoperative cortisol assay facilitates the success of catheterization. Although administration of adrenocorticotropic hormone (ACTH) has benefits such as improving the success rate, some unilateral cases could be falsely diagnosed as bilateral. Selectivity index of 5 with ACTH stimulation to assess the selectivity of catheterization and lateralization index (LI) > 4 with ACTH stimulation for unilateral diagnosis is used in many centers. Co-secretion of cortisol from the tumor potentially affects the lateralization by the LI. Patients aged <35 years with hypokalemia, marked aldosterone excess, and unilateral adrenal nodule on CT have a higher probability of unilateral disease. Patients with normokalemia, mild aldosterone excess, and no adrenal tumor on CT have a higher probability of bilateral disease. Although no methods have 100% specificity for subtype diagnosis that would allow bypassing AVS, prediction of the subtype should be considered when recommending AVS to patients. Methodological standardization and strict indication improve diagnostic quality of AVS. Development of non-invasive imaging and biochemical markers will drive a paradigm shift in the clinical practice of PA.

Keywords: Aldosterone; Adrenocorticotropic hormone; Adenoma; Catherterization; Hyperaldosteronism

INTRODUCTION

Primary hyperaldosteronism (PA) is one of the representative causes of secondary hypertension [1]. Subtype diagnosis, especially diagnosis of the unilateral subtype, which is treated by adrenal surgery, is the final and an important step of PA diagnosis. Adrenal venous sampling (AVS) has been used for over 50 years as the standard method to classify the PA subtype [2].
Since AVS is highly invasive and requires technical proficiency, adrenal computed tomography (CT) and adrenal scintigraphy replaced AVS as the first-choice method in the 1990s. However, the poor specificity of CT and poor sensitivity of scintigraphy, compared with the excellent specificity and sensitivity of AVS for detecting aldosterone-producing adenomas (APAs), have led to the revival of AVS as the gold standard for PA subtype classification and its recommendation by clinical practice guidelines [3,4] for over 20 years. Along with the awareness of PA as a common disease [5] and increased implementation of AVS in clinical practice, various approaches for technical improvement and standardization of AVS have been conducted. In this review, the methodological and clinical issues of AVS are reviewed.

HOW TO IMPROVE THE SUCCESS RATE OF AVS?

To improve the success rate of AVS, it is important to standardize the protocol at each institution depending on the experience and available facilities [6]. Identification of adrenal vein anatomy by multi-detector row CT prior to AVS is essential [7]. It is particularly important to confirm the anatomy of the right adrenal vein, for which AVS has a lower success rate compared with the left adrenal vein. Although both sequential and simultaneous catheterization and blood sampling have been adopted, no report has shown any difference in the success rate between the two approaches. Whether to use the adrenocorticotropic hormone (ACTH) or not has been a matter of debate. Use of ACTH stimulation is generally recommended because of its benefits of excluding the effect of stress during the procedure and increasing the number of successful cannulations of both adrenal veins (see next section) [8].

Catheter insertion into the adrenal vein is confirmed by intra-procedural angiography, with special care not to damage the adrenal veins [9], and interventional 3D imaging (DynaCT) during AVS [10,11]. Intraprocedural measurement of the cortisol level in the adrenal veins enables judgment of AVS success [12]. More recently, a point-of-care testing device for semiquantitative measurement of cortisol levels on site has been developed [10,13]. The combination of imaging and a biochemical approach helps improve the success of AVS.

WHAT IS THE AIM OF ACTH STIMULATION?

For evaluation of the AVS results, fluctuation of the cortisol level should be considered. Cortisol is a stress hormone that is secreted in a pulsatile fashion with diurnal rhythm. Since AVS is commonly associated with physical/psychological stress, cortisol levels may be significantly increased. This can affect the selectivity index (SI) used to evaluate successful cannulation and the lateralization index (LI) used for lateralization diagnosis [14]. Therefore, it is recommended to perform AVS without ACTH stimulation in the morning after rest and sedation for at least 15 minutes prior to minimize the effects of stress [9]. To minimize the effects of stress, AVS with ACTH stimulation is utilized in more than half of referral centers worldwide [15]. ACTH stimulation overwhelms stress-induced fluctuations in cortisol and aldosterone secretion, maximizes the cortisol level gradient between the adrenal veins and inferior vena cava, maximizes aldosterone secretion from APAs overexpressing the ACTH receptor (melanocortin 2 receptor [MC2R]), and improves the success rate of bilaterally selective catheterization [8,16,17].

On the other hand, the effects of ACTH stimulation on the diagnosis of lateralization are controversial [18]. Some studies showed that ACTH stimulation led to correct lateralization diagnosis, whereas others showed opposite results [16,19,20]. The Endocrine Society guideline neither recommends nor opposes the use of ACTH [3]. We recently demonstrated that ACTH stimulation decreased the LI and, in 22% of PA patients, changed the lateralization to bilateral from unilateral diagnosed without ACTH stimulation [21]. The patients who showed a change in the subtype from unilateral to bilateral could be divided into two subgroups. The first comprised the patients (57%) who showed a poor surgical outcome compared with the patients with a unilateral diagnosis regardless of ACTH stimulation, suggesting that lateralization by AVS with ACTH stimulation is more predictive of surgical outcome compared with AVS without ACTH stimulation. The unilateral lateralization by AVS without ACTH stimulation was assumed to be a false positive result. In contrast, the second subgroup comprised the patients (43%) who showed clinical and biochemical benefits after surgery and were diagnosed with adrenal adenomas by pathological analysis. This was the case especially when the LI in the absence of ACTH stimulation was greater than 8.3. The difference between the two subgroups could be attributed to the expression level of MC2R in the tumor: APAs with decreased expression of MC2R show an attenuated response of aldosterone secretion to ACTH and a decreased LI [22].

The method of ACTH stimulation (dosage, time of blood sampling, etc.) should be determined in advance [17,20]. If it is
given via bolus, the time between ACTH administration and blood collection should be 15 to 30 minutes, and additional infusion is needed if blood collection is not completed by 45 to 60 minutes after stimulation. The recommended dose of ACTH is 250 µg for bolus administration or 250 µg over 3 to 5 hours (50 to 83.3 µg/hr) for infusion. AVS with ACTH stimulation is recommended, considering its benefits of abolishing the interfering effects of stress, improving the rate of bilaterally selective catheterization, and identifying APAs with a good surgical outcome, particularly in low-volume center. Whether to conduct AVS with or without ACTH stimulation should be determined in individual patients after considering the cost benefit, burden on the patient, hospital facilities, and health care framework.

**WHAT ARE THE CRITERIA FOR SUCCESSFUL AVS?**

The SI, defined as the ratio of the plasma cortisol concentration in the adrenal veins to that in the inferior vena cava, is used to assess the selectivity of adrenal catheterization based on a step up of the cortisol level between the adrenal vein and inferior vena cava. A questionnaire study on AVS conducted in 24 centers worldwide revealed that approximately 60% of the centers used a SI cutoff of 2 without ACTH stimulation and of 3 to 5 with ACTH stimulation, although the cutoff values varied among the centers [15]. A recent meta-analysis demonstrated that a SI of 1.1 to 3.0 without ACTH stimulation and 3 to 5 with ACTH stimulation are commonly used cutoff values [8]. In addition, AVS with ACTH stimulation significantly increased the number of successful cannulations compared with that without ACTH stimulation [8]. Although the cannulation success rate without ACTH stimulation decreased when the SI was increased from 1.1 to 5.0, that with ACTH stimulation was unchanged when the SI increased above 2 [16]. In contrast, the success rate based on a SI ≥1.4 without ACTH stimulation was recently demonstrated to correspond to that based on a SI ≥5 with ACTH stimulation [23]. Without ACTH stimulation, accurate lateralization was attained using a SI cutoff value of 1.1, and no further improvement was attained at higher cutoff values [24]. With ACTH stimulation, however, a SI ≥5 was needed to achieve accurate lateralization [25]. Comprehensively, the SI values of 2 without ACTH stimulation and 5 with ACTH stimulation have shown robustness in many centers and are therefore recommended.

Autonomous cortisol secretion (ACS) is experienced in approximately 30% of patients with APAs [26,27], which could affect SI. Several steroid metabolites and metanephrines are potential alternative markers verifying the success of adrenal vein cannulation [28,29]. However, a recent report suggested that an increased plasma cortisol level does not affect the SI under ACTH stimulation in PA patients with subclinical Cushing’s syndrome [30]. Thus, the SI may be adopted even in patients with cortisol-co-secreting APAs.

**WHAT ARE THE CRITERIA FOR LATERALIZATION?**

Determining the laterality of excess aldosterone secretion is the goal of AVS [3]. Several criteria have been advocated (Table 1). The LI is defined as the aldosterone to cortisol concentration ratio (A/C) of the dominant side divided by that of the non-dominant side of the adrenal vein. Without ACTH stimulation decreased when the SI was increased from 1.1 to 5.0, that with ACTH stimulation was unchanged when the SI increased above 2 [16]. In contrast, the success rate based on a SI ≥1.4 without ACTH stimulation was recently demonstrated to correspond to that based on a SI ≥5 with ACTH stimulation [23]. Without ACTH stimulation, accurate lateralization was attained using a SI cutoff value of 1.1, and no further improvement was attained at higher cutoff values [24]. With ACTH stimulation, however, a SI ≥5 was needed to achieve accurate lateralization [25]. Comprehensively, the SI values of 2 without ACTH stimulation and 5 with ACTH stimulation have shown robustness in many centers and are therefore recommended.

Autonomous cortisol secretion (ACS) is experienced in approximately 30% of patients with APAs [26,27], which could affect SI. Several steroid metabolites and metanephrines are potential alternative markers verifying the success of adrenal vein cannulation [28,29]. However, a recent report suggested that an increased plasma cortisol level does not affect the SI under ACTH stimulation in PA patients with subclinical Cushing’s syndrome [30]. Thus, the SI may be adopted even in patients with cortisol-co-secreting APAs.

**WHAT ARE THE CRITERIA FOR LATERALIZATION?**

Determining the laterality of excess aldosterone secretion is the goal of AVS [3]. Several criteria have been advocated (Table 1). The LI is defined as the aldosterone to cortisol concentration ratio (A/C) of the dominant side divided by that of the non-dominant side of the adrenal vein. A LI >4 with ACTH stimulation is
the most widely accepted criterion for unilateral diagnosis. In the Primary Aldosteronism Surgical Outcome (PASO) study, which verified the prognosis of unilateral PA and proposed an international consensus, the LI >4 with ACTH stimulation was accepted as an indication for unilateral adrenalectomy [31]. The validity of the LI >4 with ACTH stimulation was verified extensively in adrenalectomized cases and demonstrated as an independent predictor of a biochemical cure and postoperative outcome at 6 months after unilateral adrenalectomy, even in older patients [32]. On the contrary, a LI <4 with ACTH stimulation [33] has been demonstrated to substantially overlap with essential hypertension [34].

The contralateral aldosterone suppression ratio (CLR), which is defined as the ratio of the aldosterone to cortisol concentrations in the non-dominant adrenal vein divided by that in the inferior vena cava or peripheral vein after ACTH stimulation, is also employed to define unilateral PA [3,33]. A CLR <1 with ACTH stimulation has been used to define suppression of contralateral aldosterone secretion [35,36]. However, no previous reports have demonstrated that the CLR is an independent predictor of unilateral PA. The CLR is recommended to be utilized in combination with the LI [37,38].

As ACS is expected to affect the lateralization diagnosis as well as the success of AVS by altering the cortisol levels in the adrenal veins, the 1 mg Dexamethasone suppression test should be conducted in patients with PA prior to AVS, especially in patients with an apparent adrenal tumor on CT. An increased cortisol level on the tumor side decreases the A/C, while a decreased cortisol level on the contralateral side increases the A/C, which may lead to a decreased LI and an incorrect lateralization diagnosis when using the LI. However, O’Ttoole et al. [30] reported that mild ACS had a limited impact on AVS parameters when using the A/C with ACTH stimulation. The ratio of the plasma aldosterone concentration (PAC) in the dominant to that in the non-dominant adrenal vein could provide an alternative marker to the LI, although no standard cutoff value has been established for this ratio. If correcting the ACS takes a higher priority than correcting the aldosterone excess, which can be managed by mineralocorticoid receptor antagonists, surgical removal of the adrenal tumor with ACS may be advocated regardless of the PA laterality. In addition, total adrenalectomy of the side of cortisol secretion and partial adrenalectomy of the side of aldosterone secretion could be considered in patients with bilateral adrenal adenomas, which secrete cortisol and aldosterone independently [39].

Comprehensively, a LI of 4 with ACTH stimulation is recommended as the standard cutoff for predicting unilateral disease. A LI >2 without ACTH stimulation [9] and a CLR <1 with ACTH stimulation can be utilized complementarily to enforce the accuracy of unilateral diagnosis. Caution should be taken in the case of possible cortisol co-secretion considering its effect on the lateralization diagnosis.

When AVS is unsuccessful and results from one side of the adrenal vein and inferior vena cava (or peripheral vein) are available, the adrenal vein/inferior vena cava (AV/IVC) index, which is calculated by dividing the aldosterone/cortisol ratio in the adrenal vein by that in the inferior vena cava, was reported to be useful for predicting laterality. Pasternak et al. [40] demonstrated that an AV/IVC index of ≤0.5 is predictive of contralateral disease, while that of ≥5.5 is predictive of ipsilateral unilateral disease. However, a multi-institutional study by Wang et al. [41] failed to validate the 100% positive predictive value of this index reported in that study. Strajina et al. [42] reported that an AV/IVC index ≤0.5 performed well in identifying patients with contralateral unilateral disease, but an index ≥5.5 was not reliable in diagnosing ipsilateral unilateral disease. When AVS of the left adrenal vein is successful, a combination of an AV/IVC index <0.5 and aldosterone/cortisol ratio <9 in the left adrenal vein was shown to predict a right unilateral lesion [43]. The specificity and positive predictive value of the AV/IVC index, however, requires further validation before it can be used in place of other criteria.

WHEN CAN WE BYPASS AVS?

No investigation has been conducted to determine a replacement for AVS as the gold standard for subtype diagnosis. However, considering various issues of AVS including invasiveness, technical requirement, cost, radiation exposure, and limited availability, it is reasonable to consider alternatives to skip AVS if applicable (Fig. 1). Patients with very high probability of unilateral disease for adrenal surgery and those with very high probability of bilateral disease for medical treatment are the candidates. Patients aged <35 years with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions on adrenal CT scan may not need AVS before unilateral adrenalectomy [3].

A recent study using the PA registry in Japan demonstrated that 90% of patients aged <35 years with hypokalemia, an elevated aldosterone level, and unilateral disease on CT showed concordance in the diagnosis by CT versus AVS. The concordance rate was lower in older patients [44]. In addition, the laterality defined by AVS was 100% concordant with the combi-
nation of unilateral disease on adrenal CT and factors including hypokalemia and a high estimated glomerular filtration rate in patients aged <40 years. CT findings alone could not confirm unilateral disease even in young patients [45].

In contrast, patients with a low PAC and aldosterone to renin ratio (ARR), obesity, female sex, normokalemia, and no adrenal tumors on CT [46-50] showed a higher risk of bilateral disease. Approximately 95% of patients with PA with normokalemia and normal adrenal CT findings had bilateral disease [46]. The prevalence of obesity was significantly higher in patients with bilateral PA compared with unilateral PA or essential hypertension [47]. Obesity and female sex were associated with bilateral PA, particularly in younger males and older females, respectively [48]. Clinical scoring of the subtype based on adrenal nodule absence on CT, low PAC and ARR, normokalemia, and female sex was predictive of bilateral PA in the validation cohort of the JPAS [49].

Nuclear imaging is another option for determining localization. Although scintigraphy using $^{131}$I-6beta-iodomethyl-19-norcholesterol as a tracer has been advocated traditionally, this probe is not specific for aldosterone production and requires dexamethasone suppression. In addition, its accumulation is affected by tumor size rather than functional activity [51], a limitation of its sensitivity. More recently, however, Yen et al. [52] reported that $^{131}$I-6beta-iodomethyl-19-norcholesterol single photon emission computed tomography (SPECT)/CT with dexamethasone suppression was useful for detecting APAs in patients with inconclusive AVS results.

Metomidate, the methylated version of etomidate, which is an imidazole-based potent inhibitor of steroid 11β-hydroxylase, is another candidate probe. Although $^{11}$C-metomidate positron emission tomography (PET), targeting CYP11B, has been reported to be useful for PA subtype classification [53], clinical application of this method is problematic due to the short half-life of $^{11}$C and the need for pretreatment with dexamethasone to block binding of the isotope to cortisol-producing CYP11B. In addition, Soinio et al. [54] reported that the concordance between AVS and $^{11}$C-metomidate PET was 55% in unilateral PA and 44% in bilateral PA and did not outperform adrenal CT. It was recently reported that the expression of chemokine receptor 4 (CXCR4), a receptor for inflammatory cytokines, is increased in aldosterone-producing tissue (particularly APA tissues) and is well correlated with the expression of CYP11B2. It was also reported that $^{68}$Ga-pentixafor PET/CT, targeting CXCR4 expression, is useful for determining the classification and lateralization of PA [55]. In addition, a CYP11B2-specific imaging agent has been developed [56,57]. Diagnosis by non-invasive imaging, which has excellent sensitivity, specificity, and cost effectiveness, is expected to provide an alternative to AVS.

New biomarkers for non-invasive subtype diagnosis have

Fig. 1. Clinical findings to bypass adrenal venous sampling (AVS) and select the appropriate treatment. As no method has 100% specificity for subtype diagnosis, AVS is indicated if the patient agrees to undergo AVS. PA, primary aldosteronism; BMI, body mass index; CT, computed tomography.

<table>
<thead>
<tr>
<th>Key clinical findings</th>
<th>Probability of the unilateral subtype</th>
<th>Level of recommendation of AVS</th>
<th>Treatment of choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young (age &lt; 35 years)</td>
<td>Hypokalemia</td>
<td>Mild aldosterone excess</td>
<td>Medical therapy without AVS if surgery not desired</td>
</tr>
<tr>
<td>Female (particularly in older patients)</td>
<td>High BMI</td>
<td>No adrenal nodule on CT</td>
<td>Adrenal surgery without AVS if agreed after careful informed consent</td>
</tr>
<tr>
<td>Normokalemia</td>
<td>High</td>
<td>Strong</td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>Weak</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Probabilty of the unilateral subtype:
- Young (age < 35 years): High
- Female (particularly in older patients): High
- Normokalemia: High
- High BMI: High
- Mild aldosterone excess: Low
- No adrenal nodule on CT: Weak
- Severe aldosterone excess: Strong
- Adrenal nodule on CT: Strong

Level of recommendation of AVS:
- Young (age < 35 years): Strong
- Female (particularly in older patients): Strong
- Normokalemia: Strong
- High BMI: Strong
- Mild aldosterone excess: Weak
- No adrenal nodule on CT: Weak
- Severe aldosterone excess: Strong
- Adrenal nodule on CT: Strong

Treatment of choice:
- Medical therapy without AVS if surgery not desired
- Adrenal surgery without AVS if agreed after careful informed consent
been identified. Steroid profiling by liquid chromatograph-mass spectrometry [58] and detection of increased 18-oxocortisol and 18-hydroxycortisol levels specifically in APAs harboring potassium inwardly rectifying channel subfamily J member 5 (KCNJ5) mutations [59,60] have been proposed as alternative methods to AVS for classifying the PA subtype. In addition, several microRNAs with differential expression in APA tissues and circulating blood [61,62] have been demonstrated as potential biomarkers useful for subtype diagnosis. Further studies to prove the specificity, sensitivity, and cost effectiveness are needed.

CONCLUSIONS

An updated overview of AVS based on stricter indications and standardized methods and decision criteria for evaluation of the results is illustrated in Fig. 2. AVS has various limitations that could interfere with its versatility and standardization. What is required for further improvement of AVS for subtype diagnosis? First, it is necessary to standardize the protocol including the need for ACTH stimulation and the optimal criteria for interpretation of the AVS results based on analysis of the postoperative outcome of PA. Second, it is necessary to reduce the invasiveness of AVS and patient burden by decreasing the test duration, radiation exposure, and complications of AVS. Third, stricter implementation and consideration of surgical candidacy prior to AVS are important to increase its diagnostic efficiency and utility [63]. Sufficient informed consent, including the probability of the expected subtype leading to the treatment choice, and a comprehensive decision considering the benefits/costs/disadvantages of AVS are essential before recommending AVS. Finally, development of non-invasive diagnostic methods including non-invasive imaging and biomarkers is expected. Non-invasive methods with comparable or better diagnostic ability, accuracy, safety, test duration, spread ability, cost effectiveness, and long-term postoperative outcomes compared with those of AVS will replace AVS as the gold standard, resulting in a paradigm shift in the clinical practice of PA.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This study was supported by the JPAS and JRAS from the Japan Agency for Medical Research and Development (AMED) under grant numbers JP17ek0109122 and JP20ek0109352 and by a research grant from the National Center for Global Health and Medicine, Japan (27-1402, 30-1008).
REFERENCES

6. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009;70:14-7.
23. Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degen-
hart C, et al. Subtyping of primary aldosteronism in the
AVIS-2 Study: assessment of selectivity and lateralization. J
Clin Endocrinol Metab 2020;105:dgz017.
24. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R,
Gallina M, Feltrin GP, et al. Identification of the etiology of
primary aldosteronism with adrenal vein sampling in pa-
ients with equivocal computed tomography and magnetic
resonance findings: results in 104 consecutive cases. J Clin
Endocrinol Metab 2001;86:1083-90.
nal venous sampling in primary aldosteronism: a low dilu-
tion of adrenal venous blood is crucial for a correct inter-
26. Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M,
Takeda Y, et al. High prevalence of diabetes in patients with
primary aldosteronism (PA) associated with subclinical hy-
percortisolism and prediabetes more prevalent in bilateral
than unilateral PA: a large, multicenter cohort study in Ja-
27. Gerards J, Heinrich DA, Adolf C, Meisinger C, Rathmann
W, Sturm L, et al. Impaired glucose metabolism in primary
aldosteronism is associated with cortisol cosecretion. J Clin
28. Lenders JWM, Eisenhofer G, Reincke M. Subtyping of pa-
tients with primary aldosteronism: an update. Horm Metab
Does concomitant autonomous adrenal cortisol overproduc-
tion have the potential to confound the interpretation of ad-
renal venous sampling in primary aldosteronism? Clin En-
docrinol (Oxf) 2015;83:456-61.
30. O’Toole SM, Sze WC, Chung TT, Akker SA, Druce MR,
Waterhouse M, et al. Low-grade cortisol cosecretion has lim-
ited impact on ACTH-stimulated AVS parameters in primary
31. Williams TA, Lenders JWM, Mulatero P, Burrello J, Rotten-
kolber M, Adolf C, et al. Outcomes after adrenalectomy for
unilateral primary aldosteronism: an international consensus
on outcome measures and analysis of remission rates in an in-
ternational cohort. Lancet Diabetes Endocrinol 2017;5:689-
99.
32. Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M,
Takeda Y, et al. Clinical characteristics and postoperative
outcomes of primary aldosteronism in the elderly. J Clin En-
docrinol Metab 2018;103:3620-9.
33. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K,
Tamura N, et al. Guidelines for the diagnosis and treatment of
primary aldosteronism: the Japan Endocrine Society 2009.
34. Umakoshi H, Naruse M, Wada N, Ichijo T, Kamemura K,
Matsuda Y, et al. Adrenal venous sampling in patients with
positive screening but negative confirmatory testing for pri-
35. Kline GA, Chin A, So B, Harvey A, Pasieka JL. Defining con-
tralateral adrenal suppression in primary aldosteronism: im-
plications for diagnosis and outcome. Clin Endocrinol (Oxf)
2015;83:20-7.
36. Wolley MJ, Gordon RD, Ahmed AH, Stowasser M. Does con-
tralateral suppression at adrenal venous sampling predict
outcome following unilateral adrenalectomy for primary al-
dosteronism? A retrospective study. J Clin Endocrinol Metab
2015;100:1477-84.
37. Umakoshi H, Tanase-Nakao K, Wada N, Ichijo T, Sone M,
Inagaki N, et al. Importance of contralateral aldosterone
suppression during adrenal vein sampling in the subtype
evaluation of primary aldosteronism. Clin Endocrinol (Oxf)
2015;83:462-7.
ical outcomes of primary aldosteronism based on later-
alization index and contralateral suppression index after ad-
renal venous sampling in real-world practice: a retrospec-
tive cohort study. BMC Endocr Disord 2020;20:114.
lateral adrenocortical masses producing aldosterone and corti-
sol independently. Endocrinol Metab (Seoul) 2015;30:607-
13.
40. Pasternak JD, Epelboym I, Seiser N, Wingo M, Herman M,
Cowan V, et al. Diagnostic utility of data from adrenal ve-
nous sampling for primary aldosteronism despite failed can-
multi-institutional comparison of adrenal venous sampling
in patients with primary aldosteronism: caution advised if
successful bilateral adrenal vein sampling is not achieved.
42. Strajina V, Al-Hilli Z, Andrews JC, Bancos I, Thompson
GB, Farley DR, et al. Primary aldosteronism: making sense
of partial data sets from failed adrenal venous sampling-
suppression of adrenal aldosterone production can be used
Adrenal Venous Sampling for Primary Hyperaldosteronism


